The pathophysiology and management of renal bone disease in dialysis patients.
As renal function declines, changes in mineral metabolism occur including phosphate retention, calcitriol deficiency, and the development of secondary hyperparathyroidism. Renal bone disease related to disordered mineral metabolism may result in increased patient morbidity and mortality. Uncontrolled parathyroid hormone (PTH) secretion will result in osteitis fibrosa, a high turnover bone disease. The use of calcium and aluminum-based phosphate binders and vitamin D sterols may contribute to the development of low turnover bone diseases such as osteomalacia and aplastic bone disease. Prevention and control of renal bone disease is an important goal for the interdisciplinary health care team. This paper discusses disordered mineral metabolism and its relationship to renal bone disease. Case studies illustrate the development and treatment of renal bone disease related to secondary hyperparathyroidism and aluminum intoxication.
Meers
C
C
Department of Nursing, Kingston General Hospital, Ontario.
Morton
A R
AR
Toffelmire
E B
EB
D000368:Aged; D001851:Bone Diseases, Metabolic / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D002292:Carcinoma, Renal Cell / Q000150:complications; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D007680:Kidney Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D009400:Nephrosclerosis / Q000150:complications; D006435:Renal Dialysis